Pfizer rises 3.0% after saying it will present infectious-disease data at IDWeek

What happened

Pfizer (PFE) rose 3.0% on October 14, 2026, after saying it will present data from more than 50 abstracts, including 12 oral presentations, on its infectious-disease pipeline at IDWeek 2026, the company said via Business Wire. The stock closed at $29.21 after opening 0.8% above the previous close. Trading volume was 1.2 times its 20-day average. The presentations are scheduled for the October 21–24, 2026 meeting in Washington, D.C.

How big was the move

The day's 3.0% rise was 2.4 times a typical daily move for this stock, a size the data classify as a large, mostly company-specific move. Pfizer outperformed the healthcare sector median by 3.8 percentage points on the day; the healthcare sector median fell 0.8% while the S&P 500 fell 1.1%. Over the last five sessions the stock rose 4.3% while the S&P 500 fell 1.1% over the same span, underscoring Pfizer's recent relative strength. The stock’s beta of 0.45 indicates it tends to move less than the market, so a move of this size stands out relative to its normal behavior.

The technical picture

Technically, the stock was 3.7% above its 20-day moving average and 5.0% above its 50-day moving average, with the 50-day average above the 200-day average — a sign of an established uptrend. Pfizer traded 10.1% above its 200-day moving average and was 0.9% below its 52-week high, having spent 49 consecutive trading days above the 200-day average. Momentum measures were moderate: the Relative Strength Index (14 days) stood at 66, inside a neutral range. Shorter- and medium-term performance shows the stock rose 6.0% over one month and 16.2% over three months, and it rose 18.1% over one year, 2.1 percentage points ahead of the S&P 500.

Fundamentals and valuation

For the four quarters through June 28, 2026, Pfizer reported revenue of $63.70 billion, a decline of 0.2% from a year earlier, and diluted earnings per share of $0.76, which fell 59.9% from a year earlier. Gross margin improved to 71.3% from 67.3% a year earlier, while operating margin narrowed to 25.1% from 29.6% a year earlier. Free-cash-flow margin was 17.2% and return on invested capital was 9.3%. The balance sheet showed net debt of 4.9 times EBITDA and share count over one year decreased by 0.1%.

On valuation, the stock trades at 38.6 times trailing earnings, a reading higher than 95% of its own readings over the past five years (five-year median: 14.4 times earnings). Price to forward earnings stood at 9.8 times expected earnings and free-cash-flow yield was 6.8%. Those measures show a contrast between a high historical multiple on trailing earnings and a lower multiple on forward expectations, reflecting recent earnings compression against forward analyst forecasts.

Earnings and analyst expectations

Pfizer last reported on August 4, 2026, with earnings per share of $0.77 against $0.68 expected, 12.9% above estimates, marking its 14th consecutive quarter beating estimates. The company’s average surprise over the last four reports was 17.7% above estimates, and the typical two-day stock reaction after recent reports was that the stock rose 0.4%. The next scheduled report is November 3, 2026.

Analysts covering the stock number 40, with a consensus rating of Hold and 40% of ratings at Buy. The consensus price target is $29.17, 0.1% below the closing price. PromtFinance scores rank Pfizer strongly for Quality and Stability and show positive Momentum, but weak Growth, underscoring a profitable, stable business with limited near-term growth expectations.

What to watch

• October 21–24, 2026: IDWeek 2026 congress in Washington, D.C., where Pfizer will present more than 50 abstracts including 12 oral presentations (Business Wire).
• November 3, 2026: next scheduled earnings report from Pfizer.
• One year performance: Pfizer rose 18.1% over one year, 2.1 percentage points ahead of the S&P 500.
• Valuation context: price to trailing earnings of 38.6 times trailing earnings, higher than 95% of its own readings over the past five years.
• Technical proximity: the stock was 0.9% below its 52-week high and 10.1% above its 200-day moving average.